<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319712455685</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319712455685</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Coronary Heart Diseases</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Association of Mean Platelet Volume and Pre- and Postinterventional Flow With Infarct-Related Artery in ST-Segment Elevation Myocardial Infarction</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Elbasan</surname>
<given-names>Zafer</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712455685">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gür</surname>
<given-names>Mustafa</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712455685">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Şahin</surname>
<given-names>Durmuş Yıldıray</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712455685">1</xref>
<xref ref-type="corresp" rid="corresp1-0003319712455685"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kuloglu</surname>
<given-names>Osman</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712455685">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Icen</surname>
<given-names>Yahya Kemal</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712455685">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Turkoglu</surname>
<given-names>Caner</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712455685">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ozkan</surname>
<given-names>Bugra</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0003319712455685">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Uysal</surname>
<given-names>Onur Kadir</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-0003319712455685">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kalkan</surname>
<given-names>Gulhan Yuksel</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712455685">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Çaylı</surname>
<given-names>Murat</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712455685">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0003319712455685">
<label>1</label>Department of Cardiology. Adana Numune Education and Research Hospital, Adana, Turkey</aff>
<aff id="aff2-0003319712455685">
<label>2</label>Department of Cardiology, Bucak State Hospital, Burdur, Turkey</aff>
<aff id="aff3-0003319712455685">
<label>3</label>Department of Cardiology, Kayseri Education and Research Hospital, Kayseri, Turkey</aff>
<author-notes>
<corresp id="corresp1-0003319712455685">Durmuş Yıldıray Şahin, Department of Cardiology, Adana Numune Education and Research Hospital, Adana 01170, Turkey. Email: <email>dysahin79@hotmail</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>64</volume>
<issue>6</issue>
<fpage>440</fpage>
<lpage>446</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Platelets play a role in the pathogenesis of ST-segment elevation myocardial infarction (STEMI). We assessed the relationship between mean platelet volume (MPV) on admission and pre- and postinterventional flow with the infarct-related artery (IRA) in patients with STEMI. We prospectively included 840 patients with STEMI who underwent primary percutaneous coronary intervention (PCI). The patients were divided into 3 groups according to MPV tertiles. Pre- and post-PCI Thrombolysis In Myocardial Infarction (TIMI) flow grade was determined. Initial TIMI flow grade 3 was accepted as patent IRA. After the primary PCI, normal flow was defined as post-PCI TIMI flow 3. When the MPV was increased, the incidence of pre-PCI patent IRA (<italic>P</italic> = .004) and post-PCI normal TIMI flow (<italic>P</italic> &lt; .001) was significantly decreased. Multivariate analysis showed that MPV was independently associated with post-PCI TIMI flow grade.</p>
</abstract>
<kwd-group>
<kwd>mean platelet volume</kwd>
<kwd>myocardial infarction</kwd>
<kwd>thrombolysis in myocardial infarction flow grade</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0003319712455685">
<title>Introduction</title>
<p>Because it offers prompt and complete recanalization of an occluded infarct-related artery (IRA), primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy for ST-segment elevation myocardial infarction (STEMI).<sup>
<xref ref-type="bibr" rid="bibr1-0003319712455685">1</xref>,<xref ref-type="bibr" rid="bibr2-0003319712455685">2</xref>
</sup> A pre-PCI patent IRA is associated with lower in-hospital mortality, higher procedural success, and better preservation of cardiac function.<sup>
<xref ref-type="bibr" rid="bibr3-0003319712455685">3</xref>,<xref ref-type="bibr" rid="bibr4-0003319712455685">4</xref>
</sup> Rapid recanalization of IRA with primary PCI is associated with improved cardiac performance and lower mortality among patients with STEMI.<sup>
<xref ref-type="bibr" rid="bibr1-0003319712455685">1</xref>,<xref ref-type="bibr" rid="bibr2-0003319712455685">2</xref>
</sup> However, despite successfully restored epicardial blood flow, microvascular reperfusion cannot be regained in all patients. This condition known as no reflow phenomenon is associated with poor functional and clinical outcomes in patients with STEMI.<sup>
<xref ref-type="bibr" rid="bibr5-0003319712455685">5</xref>
</sup>
</p>
<p>Platelets play a pivotal role in the pathogenesis of atherothrombosis.<sup>
<xref ref-type="bibr" rid="bibr6-0003319712455685">6</xref>
</sup> Mean platelet volume (MPV) is a potentially useful marker of platelet activity. Previous studies reported that MPV was higher in patients presenting with an acute STEMI.<sup>
<xref ref-type="bibr" rid="bibr7-0003319712455685">7</xref>
<xref ref-type="bibr" rid="bibr8-0003319712455685"/>–<xref ref-type="bibr" rid="bibr9-0003319712455685">9</xref>
</sup> Although MPV is associated with impaired angiographic reperfusion and poor clinical outcome in patients with STEMI,<sup>
<xref ref-type="bibr" rid="bibr10-0003319712455685">10</xref>,<xref ref-type="bibr" rid="bibr11-0003319712455685">11</xref>
</sup> little is known regarding the association between MPV levels and IRA patency in those patients.<sup>
<xref ref-type="bibr" rid="bibr12-0003319712455685">12</xref>
</sup>
</p>
<p>In this study, we aimed to assess the relationship between MPV and pre-PCI IRA patency and post-PCI Thrombolysis In Myocardial Infarction (TIMI) flow in patients with STEMI.</p>
</sec>
<sec id="section2-0003319712455685" sec-type="methods">
<title>Methods</title>
<sec id="section3-0003319712455685">
<title>Study Population</title>
<p>Between January 2011 and March 2012, 840 (622 male and 218 female; mean age 58.6 ± 12.4 years) consecutive patients with STEMI who underwent primary PCI in our clinic were prospectively included in the study. The STEMI was defined as symptoms of acute myocardial infarction (AMI) lasting ≥30 minutes with &gt;1 mm ST-segment elevation in ≥2 contiguous leads or left bundle branch block and later confirmed by the increase in troponin levels.<sup>
<xref ref-type="bibr" rid="bibr13-0003319712455685">13</xref>
</sup> Patients with the history of AMI, coronary artery bypass graft, infectious or inflammatory disease, severe liver or renal disease, neoplasm, and hematological disorders were excluded from the study. Patients who presented after &gt;12 hours of symptom onset were also not included in the study. The study was conducted according to the recommendations set forth by the Declaration of Helsinki on Biomedical Research Involving Human Subjects.<sup>
<xref ref-type="bibr" rid="bibr14-0003319712455685">14</xref>
</sup> The institutional ethics committee approved the study protocol, and each participant provided written informed consent.</p>
<p>After taking detailed medical history and physical examination, major cardiovascular risk factors including family history of CAD, current smoking status, hypertension, hyperlipidemia, and diabetes mellitus were recorded for all the patients. Also, time from onset of symptom and door-to-balloon time were noted. Fasting venous blood samples on admission were obtained from all patients to determine their plasma levels of fasting blood glucose, total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglyceride, uric acid, creatinine, and full blood count. Mean platelet volume was measured using an automated hematology analyzer Sysmex XT 1800i (Roche Diagnostic, Shanghai, China). The patients were divided into 3 groups according to the tertiles of the MPV.</p>
</sec>
<sec id="section4-0003319712455685">
<title>Echocardiography</title>
<p>Transthoracic echocardiography was performed for each patient immediately after primary PCI in intensive cardiac care unit (Vivid 7 GE Medical System, Horten, Norway). Left ventricular ejection fraction (EF) was calculated using the Simpson method.<sup>
<xref ref-type="bibr" rid="bibr15-0003319712455685">15</xref>
</sup>
</p>
</sec>
<sec id="section5-0003319712455685">
<title>Coronary Angiography and Primary PCI Procedure</title>
<p>All patients underwent urgent coronary angiography with the Judkins technique. All primary PCI procedures were performed with standard femoral approach with a 7-F guiding catheter. All patients were previously treated with aspirin and a 600-mg loading dose of clopidogrel was administered just before the index procedure. In each patient treated with tirofiban, it was administrated during or after primary PCI procedure in coronary care unit. Pre- and post-PCI IRA TIMI flow was assessed in every patient by 3 independent interventional cardiologists. A “patent” IRA is that with an initial TIMI flow grade 3 and an “occluded” artery is that with a TIMI flow grade 0, 1, or 2. After the primary PCI, no-reflow was defined as post-PCI TIMI flow grade 0, 1, or 2 and normal flow was defined as post-PCI TIMI flow grade 3.<sup>
<xref ref-type="bibr" rid="bibr5-0003319712455685">5</xref>,<xref ref-type="bibr" rid="bibr10-0003319712455685">10</xref>,<xref ref-type="bibr" rid="bibr16-0003319712455685">16</xref>
</sup>
</p>
</sec>
<sec id="section6-0003319712455685">
<title>Statistical Analysis</title>
<p>All analyses were conducted using SPSS 17.0 for Windows statistical software (SPSS Inc, Chicago, IL, USA). Continuous variables were expressed as mean ± standard deviation and categorical variables were expressed as percentages. Comparison of categorical variables between the groups was performed using the chi-square test. Analysis of variance was used in the analysis of continuous variables. Analysis of normality was performed with the Kolmogorov-Smirnov test. A stratified post hoc analysis of clinical and laboratory variables was performed according to the tertiles of the MPV. The correlation between MPV and clinical and laboratory parameters was assessed by the Pearson correlation test. Multiple linear regression analysis was performed to identify the independent predictors of MPV by including the parameters, which were correlated with MPV in bivariate analysis. Standardized β-regression coefficients and their significance from multiple linear regression analysis were reported. Optimal cutoff point of MPV level to predict post-PCI no-reflow was calculated with receiver–operating characteristic (ROC) analysis. The area under the curve (AUC) value was calculated as a measure of the accuracy of the test. A 2-sided <italic>P</italic> value <italic>&lt;</italic>.05 was considered significant.</p>
</sec>
</sec>
<sec id="section7-0003319712455685">
<title>Results</title>
<p>During the study period, 840 patients with STEMI were included. Approximately half of the patients (50.9%) had anterior MI. However, inferior location of MI was present in 345 (41.1%) patients, posterior wall MI in 57 (6.8%) patients, and high lateral MI in 10 (1.2%) patients. Drug eluting stent was used in only 139 (16.5%) patients. Pre-PCI and post-PCI flow in IRA were normal in 57 (6.8%) and 551 (65.6%) patients, respectively. Tirofiban was used in 239 (28.5%) patients. The mean MPV was 9.26 ± 1.53 fL. The MPV tertiles were defined as MPV<sub>low</sub> ≤ 8.3 fL (n = 281), MPV<sub>mid</sub> ≤ 9.9 fL (n = 279), and MPV<sub>high</sub> &gt; 9.9 fL (n = 280).</p>
<p>Baseline demographic, echocardiographic, laboratory, and hemodynamic variables of patient groups according to the tertile of MPV are compared in <xref ref-type="table" rid="table1-0003319712455685">Table 1</xref>. The mean age, gender, body mass index, systolic blood pressure, diastolic blood pressure, heart rate, EF, hypertension, smoking, hyperlipidemia, and family history were similar in the patient groups (<italic>P</italic> &gt; .05, for all). However, the incidence of diabetes mellitus, triglyceride, neutrophil-to-lymphocyte ratio, troponin, glucose levels, and usage of antidiabetic agents were significantly higher, while HDL-C and platelet counts were significantly lower in MPV<sub>high</sub> group than other groups. Also, uric acid level of MPV<sub>high</sub> group was higher than MPV<sub>low</sub> group (<italic>P</italic> = .035).</p>
<table-wrap id="table1-0003319712455685" position="float">
<label>Table 1.</label>
<caption>
<p>Comparison of Baseline Characteristics.</p>
</caption>
<graphic alternate-form-of="table1-0003319712455685" xlink:href="10.1177_0003319712455685-table1.tif"/>
<table>
<thead>
<tr>
<th>Mean Platelet Volume (MPV)</th>
<th>MPV<sub>low</sub> (≤8.3), n = 281</th>
<th>MPV<sub>mid</sub> (≤9.9), n = 279</th>
<th>MPV<sub>high</sub> (&gt;9.9), n = 280</th>
<th>
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>57.9 ± 13.01</td>
<td>58.3 ± 12</td>
<td>59.4 ± 12.1</td>
<td>.340</td>
</tr>
<tr>
<td>Females, n</td>
<td>64 (22.8%)</td>
<td>76 (27.2%)</td>
<td>84 (27.9%)</td>
<td>.325<sup>a</sup>
</td>
</tr>
<tr>
<td>BMI, kg/m<sup>2</sup>
</td>
<td>26.4 ± 2.6</td>
<td>26.4 ± 2.5</td>
<td>26.3 ± 2.6</td>
<td>.969</td>
</tr>
<tr>
<td>SBP, mm Hg</td>
<td>118.1 ± 18.3</td>
<td>119.2 ± 19.7</td>
<td>120.9 ± 21.4</td>
<td>.252</td>
</tr>
<tr>
<td>DBP, mm Hg</td>
<td>71.9 ± 13</td>
<td>72.7 ± 13.4</td>
<td>73.6 ± 13.7</td>
<td>.370</td>
</tr>
<tr>
<td>Heart rate, beats/min</td>
<td>89.7 ± 14.2</td>
<td>90.4 ± 14.1</td>
<td>90.6 ± 14.9</td>
<td>.269</td>
</tr>
<tr>
<td>Ejection fraction, %</td>
<td>45.7 ± 9.6</td>
<td>45.4 ± 9.5</td>
<td>44.9 ± 9.1</td>
<td>.615</td>
</tr>
<tr>
<td>Medical history, n (%)</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Hypertension</td>
<td>99 (35.2%)</td>
<td>117 (41.9%)</td>
<td>110 (39.3%)</td>
<td>.261<sup>a</sup>
</td>
</tr>
<tr>
<td> Diabetes mellitus</td>
<td>67 (23.8%)</td>
<td>81 (29%)</td>
<td>95 (33.9%)</td>
<td>.031<sup>a</sup>
</td>
</tr>
<tr>
<td> Smoking</td>
<td>120 (42.7%)</td>
<td>99 (35.5%)</td>
<td>113 (40.4%)</td>
<td>.204<sup>a</sup>
</td>
</tr>
<tr>
<td> Hyperlipidemia</td>
<td>68 (24.2%)</td>
<td>77 (27.6%)</td>
<td>73 (26.1%)</td>
<td>.655<sup>a</sup>
</td>
</tr>
<tr>
<td> Family history</td>
<td>86 (30.6%)</td>
<td>67 (24%)</td>
<td>71 (25.4%)</td>
<td>.176<sup>a</sup>
</td>
</tr>
<tr>
<td>Laboratory findings</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Hemoglobin, mg/dL</td>
<td>13.5 ± 1.8</td>
<td>13.4 ± 1.9</td>
<td>13.4 ± 2</td>
<td>.652</td>
</tr>
<tr>
<td> WBC, ×1000/µL</td>
<td>10.3 ± 4.1</td>
<td>9.9 ± 3.9</td>
<td>10.1 ± 3.9</td>
<td>.484</td>
</tr>
<tr>
<td> Platelet</td>
<td>261 ± 79<sup>b</sup>
</td>
<td>241 ± 62<sup>c</sup>
</td>
<td>227 ± 67</td>
<td>&lt;.001</td>
</tr>
<tr>
<td> Eosinophil, ×1000/µL</td>
<td>0.28 ± 0.17</td>
<td>0.26 ± 0.09</td>
<td>0.25 ± 0.13</td>
<td>.182</td>
</tr>
<tr>
<td> Uric acid, mg/dL</td>
<td>5.5 ± 1.4<sup>d</sup>
</td>
<td>5.7 ± 1.6</td>
<td>5.8 ± 1.7</td>
<td>.122</td>
</tr>
<tr>
<td> Creatinine, mg/dL</td>
<td>1.0 ± 0.5</td>
<td>1.0 ± 0.6</td>
<td>1.0 ± 0.7</td>
<td align="center">0747</td>
</tr>
<tr>
<td> LDL-C, mg/dL</td>
<td>120 ± 35</td>
<td>123 ± 38</td>
<td>125 ± 37</td>
<td>.329</td>
</tr>
<tr>
<td> HDL-C, mg/dL</td>
<td>39 ± 10</td>
<td>38 ± 8</td>
<td>37 ± 8<sup>d</sup>
</td>
<td>.007</td>
</tr>
<tr>
<td> Triglyceride, mg/dL</td>
<td>137 ± 129</td>
<td>147 ± 94</td>
<td>161 ± 116<sup>e</sup>
</td>
<td>.05</td>
</tr>
<tr>
<td> Total cholesterol, mg/dL</td>
<td>187 ± 51</td>
<td>188 ± 42</td>
<td>194 ± 43</td>
<td>.107</td>
</tr>
<tr>
<td> Glucose, mg/dL</td>
<td>136 ± 65</td>
<td>146 ± 80</td>
<td>162 ± 94<sup>f</sup>
</td>
<td>.001</td>
</tr>
<tr>
<td> CK-MB, ng/mL</td>
<td>81 ± 95</td>
<td>92 ± 101</td>
<td>95 ± 109</td>
<td>.260</td>
</tr>
<tr>
<td> Troponin, ng/mL</td>
<td>11.8 ± 9.5</td>
<td>14.3 ± 12.4</td>
<td>17.3 ± 19.1<sup>g</sup>
</td>
<td>&lt;.001</td>
</tr>
<tr>
<td> N-to-L ratio</td>
<td>4.7 ± 3.2</td>
<td>5 ± 3.4</td>
<td>5.8 ± 4<sup>h</sup>
</td>
<td>.001</td>
</tr>
<tr>
<td>Prehospital medications, n (%)</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> β-Blocker use</td>
<td>22 (7.8%)</td>
<td>28 (10%)</td>
<td>25 (8.9%)</td>
<td>.658</td>
</tr>
<tr>
<td> Statin use</td>
<td>68 (24.2%)</td>
<td>77 (27.6%)</td>
<td>73 (26.1%)</td>
<td>.655</td>
</tr>
<tr>
<td> ACE inhibitor use</td>
<td>63 (22.4%)</td>
<td>71 (25.4%)</td>
<td>65 (23.2%)</td>
<td>.683<sup>a</sup>
</td>
</tr>
<tr>
<td> ARB use</td>
<td>45 (16%)</td>
<td>47 (16.8%)</td>
<td>60 (21.4%)</td>
<td>.200<sup>a</sup>
</td>
</tr>
<tr>
<td> Antidiabetic drugs</td>
<td>67 (23.8%)</td>
<td>81 (29%)</td>
<td>95 (33.9%)</td>
<td>.031<sup>a</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0003319712455685">
<p>Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; CK-MB, creatine kinase MB; DBP, diastolic blood pressure; HDL, high-density cholesterol; LDL-C, low-density cholesterol; N-to-L ratio, neutrophil-to-lymphocyte ratio; SBP, systolic blood pressure; WBC, white blood cell count.</p>
</fn>
<fn id="table-fn2-0003319712455685">
<p>
<sup>a</sup> chi-square test.</p>
</fn>
<fn id="table-fn3-0003319712455685">
<p>
<sup>b</sup> <italic>P</italic> &lt; .001 versus MPV<sub>high</sub> and <italic>P</italic> = .001 versus MPV<sub>mid</sub> groups.</p>
</fn>
<fn id="table-fn4-0003319712455685">
<p>
<sup>c</sup> <italic>P</italic> = .021 versus MPV<sub>high</sub> group.</p>
</fn>
<fn id="table-fn5-0003319712455685">
<p>
<sup>d</sup> <italic>P</italic> = .002 versus MPV<sub>low</sub> group.</p>
</fn>
<fn id="table-fn6-0003319712455685">
<p>
<sup>e</sup> <italic>P</italic> = .015 versus MPV<sub>low</sub> group.</p>
</fn>
<fn id="table-fn7-0003319712455685">
<p>
<sup>f</sup> <italic>P</italic> &lt; .001 versus MPV<sub>low</sub> group and <italic>P</italic> = .017 versus MPV<sub>mid</sub> group.</p>
</fn>
<fn id="table-fn8-0003319712455685">
<p>
<sup>g</sup> <italic>P</italic> &lt; .001 versus MPV<sub>low</sub> group and <italic>P</italic> = .009 versus MPV<sub>mid</sub> group.</p>
</fn>
<fn id="table-fn9-0003319712455685">
<p>
<sup>h</sup> <italic>P </italic>&lt; .001 versus MPV<sub>low</sub> group and <italic>P</italic> = .009 versis MPV<sub>mid</sub> group.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Type of infarction, stent type, and size were similar between groups. When the MPV was increased, the incidence of pre-PCI patent IRA and post-PCI normal TIMI flow was significantly decreased. Due to increased incidence of post-PCI no reflow, the use of tirofiban significantly increased in the MPV<sub>high</sub> group. Clinical and interventional characteristics of patients were shown in <xref ref-type="table" rid="table2-0003319712455685">Table 2.</xref>
</p>
<table-wrap id="table2-0003319712455685" position="float">
<label>Table 2.</label>
<caption>
<p>Clinical and Procedural Characteristics.</p>
</caption>
<graphic alternate-form-of="table2-0003319712455685" xlink:href="10.1177_0003319712455685-table2.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>MPV<sub>low</sub> (≤8.3), n = 281</th>
<th>MPV<sub>mid</sub> (≤9.9), n = 279</th>
<th>MPV<sub>high</sub> (&gt;9.9), n = 280</th>
<th>
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chest pain time, h</td>
<td>4.6 ± 3.5</td>
<td>4.6 ± 3.5</td>
<td>4.9 ± 6.5</td>
<td>.728</td>
</tr>
<tr>
<td>Door-balloon time, min</td>
<td>32.1 ± 7.8</td>
<td>31.8 ± 7.5</td>
<td>32.1 ± 7.2</td>
<td>.933</td>
</tr>
<tr>
<td>Type of infarction, n (%)</td>
<td>
<bold>
</bold>
</td>
<td>
<bold>
</bold>
</td>
<td>
<bold>
</bold>
</td>
<td>.541</td>
</tr>
<tr>
<td> Anterior MI</td>
<td>136 (48.4)</td>
<td>145 (52.0)</td>
<td>147 (52.5)</td>
<td>
</td>
</tr>
<tr>
<td> Inferior MI</td>
<td>121 (43.1)</td>
<td>114 (40.9)</td>
<td>110 (39.3)</td>
<td>
</td>
</tr>
<tr>
<td> Posterior MI</td>
<td>23 (8.2)</td>
<td>15 (5.4)</td>
<td>19 (6.8)</td>
<td>
</td>
</tr>
<tr>
<td> High lateral MI </td>
<td>1 (0.4)</td>
<td>5 (1.8)</td>
<td>4 (1.4)</td>
<td>
</td>
</tr>
<tr>
<td>Type of stent, n (%)</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>.186</td>
</tr>
<tr>
<td> Bare metal</td>
<td>230 (81.9)</td>
<td>242 (86.7)</td>
<td>229 (81.8) </td>
<td>
</td>
</tr>
<tr>
<td> Drug eluting</td>
<td>51 (18.1)</td>
<td>37 (13.3)</td>
<td>51 (18.2)</td>
<td>
</td>
</tr>
<tr>
<td>Stent size</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Length</td>
<td>17.6 ± 4.6</td>
<td>17.9 ± 4.7</td>
<td>17.9 ± 4.9</td>
<td>.677</td>
</tr>
<tr>
<td> Diameter</td>
<td>3.13 ± 0.41</td>
<td>3.15 ± 0.44</td>
<td>3.09 ± 0.37</td>
<td>.160</td>
</tr>
<tr>
<td>Pre-PCI patent IRA, n (%)</td>
<td>23 (8.2)</td>
<td>19 (6.8)</td>
<td>12 (4.3)</td>
<td>.004</td>
</tr>
<tr>
<td>Post-PCI TIMI Flow, n (%)</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>&lt;.001</td>
</tr>
<tr>
<td> No reflow</td>
<td>69 (24.6)</td>
<td>77 (27.6)</td>
<td>143 (51.1)</td>
<td>
</td>
</tr>
<tr>
<td> Normal flow</td>
<td>212 (75.4)</td>
<td>202 (72.4)</td>
<td>137 (48.9)</td>
<td>
</td>
</tr>
<tr>
<td>Tirofiban use, n (%)</td>
<td>65 (23.1)</td>
<td>79 (28.3)</td>
<td>95 (33.9)</td>
<td>.018</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn10-0003319712455685">
<p>Abbreviations: MPV, mean platelet volume; MI, myocardial infarction; PCI, percutaneous coronary intervention; IRA, infarct-related artery, TIMI, thrombolysis in myocardial infarction.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Bivariate and multivariate relationships of the MPV level in patient groups were reported in <xref ref-type="table" rid="table3-0003319712455685">Table 3</xref>. The MPV level was significantly correlated with diabetes (<italic>P</italic> = .005), total cholesterol (<italic>P</italic> = .048), HDL-C (<italic>P</italic> = .028), glucose (<italic>P</italic> &lt; .001), uric acid (<italic>P</italic> = .015), troponin (<italic>P</italic> &lt; .001), platelet (<italic>P</italic> &lt; .001), neutrophil-to-lymphocyte ratio (<italic>P</italic> &lt; .001), antidiabetic drug use (<italic>P</italic> &lt; .005), tirofiban use (<italic>P</italic> = .026), pre-PCI IRA patency (<italic>P</italic> = .012), and post-PCI TIMI flow grade (<italic>P</italic> &lt; .001) on Pearson correlation analysis. However, multivariate regression analysis showed that MPV was independently associated with diabetes (β = 0.113, <italic>P</italic> = .001), troponin levels (β = 0.153, <italic>P</italic> &lt; .001), platelet counts (β = −0.195, <italic>P</italic> &lt; .001), and post-PCI TIMI flow grade (β = −0.214, <italic>P</italic> &lt; .001). But MPV was not an independent predictor of pre-PCI IRA patency (β = −0.012, <italic>P</italic> &gt; .734). The cutoff value of MPV obtained by the ROC curve analysis was 9.05 fL for predicting of post-PCI no reflow (sensitivity: 67.8%, specificity: 64.1%, <xref ref-type="fig" rid="fig1-0003319712455685">Figure 1</xref>). The AUC was measured as 0.734 (<italic>P</italic> &lt; .001).</p>
<fig id="fig1-0003319712455685" position="float">
<label>Figure 1.</label>
<caption>
<p>Receiver–operating characteristic (ROC) curve of mean platelet volume (MPV) for predicting angiographic no reflow. The area under the ROC curve = 0.734 (95% confidence interval 0.698-0.771).</p>
</caption>
<graphic xlink:href="10.1177_0003319712455685-fig1.tif"/>
</fig>
<table-wrap id="table3-0003319712455685" position="float">
<label>Table 3.</label>
<caption>
<p>Bivariate and Multivariate Relationships of the MPV in Patient Group (n = 840).</p>
</caption>
<graphic alternate-form-of="table3-0003319712455685" xlink:href="10.1177_0003319712455685-table3.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Pearson Correlation Coefficient</th>
<th>
<italic>P</italic>
</th>
<th>Standardized β-Regression Coefficients<sup>a</sup>
</th>
<th>
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>.066</td>
<td>.055</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>BMI</td>
<td>.001</td>
<td>.975</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>EF (%)</td>
<td>
</td>
<td>−.031</td>
<td>.374</td>
<td>
</td>
</tr>
<tr>
<td>Gender, F/M</td>
<td>.066</td>
<td>.055</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>Family history</td>
<td>
</td>
<td>.021</td>
<td>.536</td>
<td>
</td>
</tr>
<tr>
<td>DM</td>
<td>.097</td>
<td>.005</td>
<td>.113</td>
<td>.001</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>.014</td>
<td>.681</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>Hypertension</td>
<td>.030</td>
<td>.385</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>Smoking</td>
<td>.030</td>
<td>.385</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>Heart rate, beats/min</td>
<td>
</td>
<td>.019</td>
<td>.589</td>
<td>
</td>
</tr>
<tr>
<td>Triglyceride, mg/dL</td>
<td>.068</td>
<td>.055</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>.070</td>
<td>.048</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dL</td>
<td>.031</td>
<td>.380</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dL</td>
<td>−.078</td>
<td>.028</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>Glucose, mg/dL</td>
<td>.129</td>
<td>&lt;.001</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>Uric acid</td>
<td>.085</td>
<td>.015</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>CK-MB</td>
<td>.045</td>
<td>.195</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>Troponin</td>
<td>.149</td>
<td>&lt;.001</td>
<td>.153</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>N-to-L ratio</td>
<td>.136</td>
<td>&lt;.001</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>Platelet</td>
<td>−.245</td>
<td>&lt;.001</td>
<td>−.195</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Statin use</td>
<td>.014</td>
<td>.681</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>Antidiabetic use</td>
<td>.097</td>
<td>.005</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>ARB use</td>
<td>.051</td>
<td>.143</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>ACEI use</td>
<td>.022</td>
<td>.517</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>Beta-blocker use</td>
<td>.028</td>
<td>.415</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>Tirofiban use</td>
<td>.077</td>
<td>.026</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>Post-PCI TIMI flow grade</td>
<td>−.278</td>
<td>&lt;.001</td>
<td>−.214</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Pre-PCI IRA patency</td>
<td>−.087</td>
<td>.012</td>
<td>
</td>
<td>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn12-0003319712455685">
<p>Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CK-MB, creatine kinase MB; DM, diabetes mellitus; F, female; HDL, high-density lipoprotein; IRA, infarct-related artery, LDL, low-density lipoprotein; M, male; MPV, mean platelet volume; PCI, percutaneous coronary intervention; N-to-L ratio, neutrophil-to-lymphocyte ratio; TIMI, thrombolysis in myocardial infarction; WBC, white blood cell count.</p>
</fn>
<fn id="table-fn13-0003319712455685">
<p>
<sup>a</sup> From multiple linear regression.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section8-0003319712455685">
<title>Discussion</title>
<p>Our main findings were (1) MPV was weakly associated with pre-PCI IRA patency in bivariate analysis but not an independent predictor of pre-PCI IRA patency and (2) MPV was an independent predictor of post-PCI TIMI flow grade.</p>
<p>Platelets can release mediators of coagulation, inflammation, thrombosis, and atherosclerosis.<sup>
<xref ref-type="bibr" rid="bibr17-0003319712455685">17</xref>,<xref ref-type="bibr" rid="bibr18-0003319712455685">18</xref>
</sup> They are heterogeneous in size and have hemostatic potential.<sup>
<xref ref-type="bibr" rid="bibr19-0003319712455685">19</xref>,<xref ref-type="bibr" rid="bibr20-0003319712455685">20</xref>
</sup> It has been known that platelet size, measured as MPV, correlates with their reactivity. Larger circulating platelets contain more granules and produce greater amounts of vasoactive and prothrombotic factors and aggregate more rapidly under agonists stimulus.<sup>
<xref ref-type="bibr" rid="bibr17-0003319712455685">17</xref>,<xref ref-type="bibr" rid="bibr20-0003319712455685">20</xref>
</sup>
</p>
<p>Circulating platelets have a pivotal role in the pathogenesis of STEMI contributing to the thrombotic occlusion of the IRA.<sup>
<xref ref-type="bibr" rid="bibr6-0003319712455685">6</xref>,<xref ref-type="bibr" rid="bibr12-0003319712455685">12</xref>,<xref ref-type="bibr" rid="bibr19-0003319712455685">19</xref>
</sup> To our knowledge, only 1 study investigated the relationship between MPV and preprimary PCI IRA patency. In that study, Estévez-Loureiro et al<sup>
<xref ref-type="bibr" rid="bibr12-0003319712455685">12</xref>
</sup> investigated the relationship between MPV on admission and preprimary PCI IRA patency in 617 patients with STEMI. They found that MPV was a predictor of preprimary PCI IRA patency in patients with STEMI. In our study, MPV was weakly associated with pre-PCI IRA patency and not an independent predictor of those. A possible reason for this discrepancy is glycoprotein IIb/IIIa inhibitor use. They used abciximab in 61% of patients before arrival to the catheterization laboratory. But current guidelines recommended selective downstream administration of glycoprotein IIb/IIIa inhibitor in patients with STEMI,<sup>
<xref ref-type="bibr" rid="bibr21-0003319712455685">21</xref>
</sup> and we used selective downstream tirofiban in only 28.5% of patients.</p>
<p>It has been shown that MPV can also affect the outcome of primary PCI in patients with STEMI.<sup>
<xref ref-type="bibr" rid="bibr10-0003319712455685">10</xref>,<xref ref-type="bibr" rid="bibr11-0003319712455685">11</xref>
</sup> Higher MPV may correspond with the increased number of both platelet–leukocyte and platelet–platelet aggregates. During the reperfusion of IRA, platelet–platelet aggregates or leukocyte–platelet complexes can plug coronary microvessels, resulting in impairment of coronary flow.<sup>
<xref ref-type="bibr" rid="bibr10-0003319712455685">10</xref>,<xref ref-type="bibr" rid="bibr22-0003319712455685">22</xref>,<xref ref-type="bibr" rid="bibr23-0003319712455685">23</xref>
</sup> Huczek et al<sup>
<xref ref-type="bibr" rid="bibr10-0003319712455685">10</xref>
</sup> showed that MPV is a strong, independent predictor of impaired angiographic reperfusion and 6-month mortality in STEMI treated with primary PCI. In our study, in accordance with the previous study, MPV on admission was independently associated with impaired reperfusion in patients with STEMI treated with primary PCI.</p>
<p>Platelet count alterations also occur during the course of acute MI. On admission, patients with MI had significantly lower platelet counts compared with healthy controls and patients with other vascular diseases.<sup>
<xref ref-type="bibr" rid="bibr24-0003319712455685">24</xref>,<xref ref-type="bibr" rid="bibr25-0003319712455685">25</xref>
</sup> These changes probably occurred in parallel with alterations in platelet size and function and correlate with infarct size as indicated by the level of lactic dehydrogenase activity.<sup>
<xref ref-type="bibr" rid="bibr24-0003319712455685">24</xref>,<xref ref-type="bibr" rid="bibr26-0003319712455685">26</xref>
</sup> Avramakis et al<sup>
<xref ref-type="bibr" rid="bibr27-0003319712455685">27</xref>
</sup> investigated the changes in platelets and white blood cell subpopulations among patients with acute coronary syndrome (86 with acute MI and 81 unstable angina pectoris) and found significant decrease in platelet counts and eosinophil percentages during acute MI, when compared with the controls. Mikhailidis et al<sup>
<xref ref-type="bibr" rid="bibr28-0003319712455685">28</xref>
</sup> reported that platelets were hyperaggregable in patients with acute MI. This phenomenon may reflect the increased consumption of platelets in acute MI. In our study, we also found that the MPV was independently associated with platelet count but not correlated with eosinophil percentage.</p>
<p>In present study, MPV was independently associated with diabetes. This condition is consistent with the previous studies.<sup>
<xref ref-type="bibr" rid="bibr29-0003319712455685">29</xref>
<xref ref-type="bibr" rid="bibr30-0003319712455685"/>–<xref ref-type="bibr" rid="bibr31-0003319712455685">31</xref>
</sup> Platelets may also be involved in the pathogenesis of the atherothrombotic complications associated with diabetes mellitus.<sup>
<xref ref-type="bibr" rid="bibr32-0003319712455685">32</xref>,<xref ref-type="bibr" rid="bibr33-0003319712455685">33</xref>
</sup> The mechanism may be the increased platelet reactivity due to the direct effect of hyperglycemia via osmotic effects on platelets.<sup>
<xref ref-type="bibr" rid="bibr34-0003319712455685">34</xref>
</sup> Insulin resistance, diabetes mellitus, and other risk factors associated with endothelial dysfunction might trigger a series of cytokine production which in turn may stimulate the production of large platelets in the bone marrow.<sup>
<xref ref-type="bibr" rid="bibr17-0003319712455685">17</xref>
</sup>
</p>
<p>In our study, the independent relationship between MPV and troponin level is not surprise. A similar result was observed in a study by Estévez-Loureiro et al.<sup>
<xref ref-type="bibr" rid="bibr12-0003319712455685">12</xref>
</sup> In that study, they speculated that more reactive platelets were associated with a more severe vessel thrombosis, a more persistent occlusion of the IRA and subsequently larger ischemic damage.<sup>
<xref ref-type="bibr" rid="bibr12-0003319712455685">12</xref>
</sup>
</p>
</sec>
<sec id="section9-0003319712455685">
<title>Conclusions</title>
<p>Our study showed that MPV on admission, a marker of platelet function, was weakly correlated with pre-PCI IRA patency in bivariate analysis but not with independent predictor of pre-PCI IRA patency in multivariate regression analysis. However, it was an independent predictor of post-PCI TIMI flow grade. There was also significant association between MPV and troponin levels, platelet counts, and diabetes. Higher MPV may play a role in impaired microvascular reperfusion and infarct size in patients with STEMI who underwent primary PCI. Hence, it may help in planning adjunctive therapy to improve the outcome of primary PCI.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0003319712455685">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0003319712455685">
<label>Funding</label>
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319712455685">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grines</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zijlstra</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Weaver</surname>
<given-names>WD</given-names>
</name>
<name>
<surname>Granger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Simes</surname>
<given-names>RJ</given-names>
</name>
</person-group>. <article-title>Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials</article-title>. <source>Am Heart J</source>. <year>2003</year>;<volume>145</volume>(<issue>1</issue>):<fpage>47</fpage>–<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr2-0003319712455685">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keeley</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Boura</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Grines</surname>
<given-names>CL</given-names>
</name>
</person-group>. <article-title>Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials</article-title>. <source>Lancet</source>. <year>2003</year>;<volume>361</volume>(<issue>9351</issue>):<fpage>13</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr3-0003319712455685">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brodie</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Stuckey</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Muncy</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction</article-title>. <source>Am J Cardiol</source>. <year>2000</year>;<volume>85</volume>(<issue>1</issue>):<fpage>13</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr4-0003319712455685">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stone</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials</article-title>. <source>Circulation</source>. <year>2001</year>;<volume>104</volume>(<issue>6</issue>):<fpage>636</fpage>–<lpage>641</lpage>.</citation>
</ref>
<ref id="bibr5-0003319712455685">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rezkalla</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Dharmashankar</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Abdalrahman</surname>
<given-names>IB</given-names>
</name>
<name>
<surname>Kloner</surname>
<given-names>RA</given-names>
</name>
</person-group>. <article-title>No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy</article-title>. <source>J Interv Cardiol</source>. <year>2010</year>;<volume>23</volume>(<issue>5</issue>):<fpage>429</fpage>–<lpage>436</lpage>.</citation>
</ref>
<ref id="bibr6-0003319712455685">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Patrono</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Platelet activation and atherothrombosis</article-title>. <source>N Engl J Med</source>. <year>2007</year>;<volume>357</volume>(<issue>24</issue>):<fpage>2482</fpage>–<lpage>2494</lpage>.</citation>
</ref>
<ref id="bibr7-0003319712455685">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cameron</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ibbotson</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Carson</surname>
<given-names>PH</given-names>
</name>
</person-group>. <article-title>Platelet size in myocardial infarction</article-title>. <source>Br Med J (Clin Res Ed)</source>. <year>1983</year>;<volume>287</volume>(<issue>6390</issue>):<fpage>449</fpage>–<lpage>451</lpage>.</citation>
</ref>
<ref id="bibr8-0003319712455685">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kilicli-Camur</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Demirtunc</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Konuralp</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Eskiser</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Başaran</surname>
<given-names>Y.</given-names>
</name>
</person-group> <article-title>Could mean platelet volume be a predictive marker for acute myocardial infarction?</article-title> <source>Med Sci Monit</source>. <year>2005</year>;<volume>11</volume>(<issue>8</issue>):<fpage>CR387</fpage>–<lpage>CR392</lpage>.</citation>
</ref>
<ref id="bibr9-0003319712455685">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozkan</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Uysal</surname>
<given-names>OK</given-names>
</name>
<name>
<surname>Duran</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Relationship between mean platelet volume and atherosclerosis in young patients with ST elevation myocardial infarction [published online June 4, 2012]</article-title>. <source>Angiology</source>. <year>2012</year>. <comment>doi:10.1177/0003319712448834</comment>.</citation>
</ref>
<ref id="bibr10-0003319712455685">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huczek</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Kochman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Filipiak</surname>
<given-names>KJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention</article-title>. <source>J Am Coll Cardiol</source>. <year>2005</year>;<volume>46</volume>(<issue>2</issue>):<fpage>284</fpage>–<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr11-0003319712455685">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maden</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Kacmaz</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Selcuk</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Relationship of admission hematological indexes with myocardial reperfusion abnormalities in acute ST segment elevation myocardial infarction patients treated with primary percutaneous coronary interventions</article-title>. <source>Can J Cardiol</source>. <year>2009</year>;<volume>25</volume>(<issue>6</issue>):<fpage>e164</fpage>–<lpage>e168</lpage>.</citation>
</ref>
<ref id="bibr12-0003319712455685">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Estévez-Loureiro</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Salgado-Fernández</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Marzoa-Rivas</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Mean platelet volume predicts patency of the infarct-related artery before mechanical reperfusion and short-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention</article-title>. <source>Thromb Res</source>. <year>2009</year>;<volume>124</volume>(<issue>5</issue>):<fpage>536</fpage>–<lpage>540</lpage>.</citation>
</ref>
<ref id="bibr13-0003319712455685">
<label>13</label>
<citation citation-type="journal">
<article-title>Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction</article-title>. <source>Eur Heart J</source>. <year>2000</year>;<volume>21</volume>(<issue>18</issue>):<fpage>1502</fpage>–<lpage>1513</lpage>.</citation>
</ref>
<ref id="bibr14-0003319712455685">
<label>14</label>
<citation citation-type="journal">
<collab collab-type="author">World Medical Association declaration of Helsinki</collab>. <article-title>Recommendations guiding physicians in biomedical research involving human subjects</article-title>. <source>JAMA</source>. <year>1997</year>;<volume>19</volume>;<issue>277(11)</issue>:<fpage>925</fpage>–<lpage>926</lpage>.</citation>
</ref>
<ref id="bibr15-0003319712455685">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schiller</surname>
<given-names>NB</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms</article-title>. <source>J Am Soc Echocardiogr</source>. <year>1989</year>;<volume>2</volume>(<issue>5</issue>):<fpage>358</fpage>–<lpage>367</lpage>.</citation>
</ref>
<ref id="bibr16-0003319712455685">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niccoli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Marino</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Spaziani</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Crea</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Prevention and treatment of no-reflow</article-title>. <source>Acute Card Care</source>. <year>2010</year>;<volume>12</volume>(<issue>3</issue>):<fpage>81</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr17-0003319712455685">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vizioli</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Muscari</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Muscari</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases</article-title>. <source>Int J Clin Pract</source>. <year>2009</year>;<volume>63</volume>(<issue>10</issue>):<fpage>1509</fpage>–<lpage>1515</lpage>.</citation>
</ref>
<ref id="bibr18-0003319712455685">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gawaz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Langer</surname>
<given-names>H</given-names>
</name>
<name>
<surname>May</surname>
<given-names>AE</given-names>
</name>
</person-group>. <article-title>Platelets in inflammation and atherogenesis</article-title>. <source>J Clin Invest</source>. <year>2005</year>;<volume>115</volume>(<issue>12</issue>):<fpage>3378</fpage>–<lpage>3384</lpage>.</citation>
</ref>
<ref id="bibr19-0003319712455685">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serebruany</surname>
<given-names>VL</given-names>
</name>
<name>
<surname>Malinin</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Callahan</surname>
<given-names>KP</given-names>
</name>
<etal/>
</person-group>. <article-title>Assessment of the Safety and Efficacy of a New Thrombolytic Agent platelet substudy. Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy</article-title>. <source>Am Heart J</source>. <year>2003</year>;<volume>145</volume>(<issue>4</issue>):<fpage>636</fpage>–<lpage>642</lpage>.</citation>
</ref>
<ref id="bibr20-0003319712455685">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Loo</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>JF</given-names>
</name>
</person-group>. <article-title>Megakaryocytes and platelets in vascular disease</article-title>. <source>Baillieres Clin Haematol</source>. <year>1997</year>;<volume>10</volume>(<issue>1</issue>):<fpage>109</fpage>–<lpage>123</lpage>.</citation>
</ref>
<ref id="bibr21-0003319712455685">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wijns</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Kolh</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Danchin</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI), Guidelines on myocardial revascularization</article-title>. <source>Eur Heart J</source>. <year>2010</year>;<volume>31</volume>(<issue>20</issue>):<fpage>2501</fpage>–<lpage>2555</lpage>.</citation>
</ref>
<ref id="bibr22-0003319712455685">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lefer</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Scalia</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lefer</surname>
<given-names>DJ.</given-names>
</name>
</person-group> <article-title>Synergism between platelets and neutrophils in provoking cardiac dysfunction after ischemia and reperfusion: role of selectins</article-title>. <source>Circulation</source>. <year>1998</year>;<volume>98</volume>(<issue>13</issue>):<fpage>1322</fpage>–<lpage>1328</lpage>.</citation>
</ref>
<ref id="bibr23-0003319712455685">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Engler</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Schmid-Schönbein</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Pavelec</surname>
<given-names>RS</given-names>
</name>
</person-group>. <article-title>Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog</article-title>. <source>Am J Pathol</source>. <year>1983</year>;<volume>111</volume>(<issue>1</issue>):<fpage>98</fpage>–<lpage>111</lpage>.</citation>
</ref>
<ref id="bibr24-0003319712455685">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glud</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>EB</given-names>
</name>
<name>
<surname>Kristensen</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Arnfred</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Platelet number and volume during myocardial infarction in relation to infarct size</article-title>. <source>Acta Med Scand</source>. <year>1986</year>;<volume>220</volume>(<issue>5</issue>):<fpage>401</fpage>–<lpage>405</lpage>.</citation>
</ref>
<ref id="bibr25-0003319712455685">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cameron</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ibbotson</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Carson</surname>
<given-names>PH</given-names>
</name>
</person-group>. <article-title>Platelet size in myocardial infarction</article-title>. <source>Br Med J (Clin Res Ed)</source>. <year>1983</year>;<volume>287</volume>(<issue>6390</issue>):<fpage>449</fpage>–<lpage>451</lpage>.</citation>
</ref>
<ref id="bibr26-0003319712455685">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fager</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sjogren</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sjogren</surname>
<given-names>U</given-names>
</name>
</person-group>. <article-title>Platelet counts in myocardial infarction, angina pectoris and peripheral artery disease</article-title>. <source>Acta Med Scand</source>. <year>1985</year>;<volume>217</volume>(<issue>1</issue>):<fpage>21</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr27-0003319712455685">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Avramakis</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Papadimitraki</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Papakonstandinou</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Platelets and white blood cell subpopulations among patients with myocardial infarction and unstable angina</article-title>. <source>Platelets</source>. <year>2007</year>;<volume>18</volume>(<issue>1</issue>):<fpage>16</fpage>–<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr28-0003319712455685">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Barradas</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Mier</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Platelet function in patients admitted with a diagnosis of myocardial infarction</article-title>. <source>Angiology</source>. <year>1987</year>;<volume>38</volume>(<issue>1 pt 1</issue>):<fpage>36</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr29-0003319712455685">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zuberi</surname>
<given-names>BF</given-names>
</name>
<name>
<surname>Akhtar</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Afsar</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Comparison of mean platelet volume in patients with diabetes mellitus, impaired fasting glucose and non-diabetic subjects</article-title>. <source>Singapore Med J</source>. <year>2008</year>;<volume>49</volume>(<issue>2</issue>):<fpage>114</fpage>–<lpage>116</lpage>.</citation>
</ref>
<ref id="bibr30-0003319712455685">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>XW</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>HQ</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>XQ</given-names>
</name>
<name>
<surname>Ran</surname>
<given-names>XW</given-names>
</name>
</person-group>. <article-title>Variance of mean platelet volume in subjects with normal glucose tolerance, impaired glucose regulation and type 2 diabetic mellitus and its relationship with diabetic peripheral artery disease</article-title>. <source>Zhonghua Yi Xue Za Zhi</source>. <year>2012</year>;<volume>92</volume>(<issue>4</issue>):<fpage>232</fpage>–<lpage>235</lpage>.</citation>
</ref>
<ref id="bibr31-0003319712455685">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tavil</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sen</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Yazici</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Coronary heart disease is associated with mean platelet volume in type 2 diabetic patients</article-title>. <source>Platelets</source>. <year>2010</year>;<volume>21</volume>(<issue>5</issue>):<fpage>368</fpage>–<lpage>372</lpage>.</citation>
</ref>
<ref id="bibr32-0003319712455685">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jagroop</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
</person-group>. <article-title>Mean platelet volume in patients with type 2 diabetes mellitus</article-title>. <source>Platelets</source>. <year>2005</year>;<volume>16</volume>(<issue>3-4</issue>):<fpage>219</fpage>–<lpage>220</lpage>.</citation>
</ref>
<ref id="bibr33-0003319712455685">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beckmann</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Creager</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Libby</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Diabetes and atherosclerosis: epidemiology, pathophysiology and management</article-title>. <source>JAMA</source>. <year>2002</year>;<volume>287</volume>(<issue>19</issue>):<fpage>2570</fpage>–<lpage>2581</lpage>.</citation>
</ref>
<ref id="bibr34-0003319712455685">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keating</surname>
<given-names>FK</given-names>
</name>
<name>
<surname>Sobel</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>DJ</given-names>
</name>
</person-group>. <article-title>Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus</article-title>. <source>Am J Cardiol</source>. <year>2003</year>;<volume>92</volume>(<issue>11</issue>):<fpage>1362</fpage>–<lpage>1365</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>